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Abstract 
The primary aim of this systematic review and meta-analysis was to assess the proportion of patients 
with Treatment Resistant Schizophrenia (TRS) respond to ECT augmentation of clozapine (C+ECT). 
We searched major electronic databases from 1980 to July 2015.  We conducted a random effects 
meta-analysis reporting the proportion of responders to C+ECT in RCTs and open-label trials. Five 
clinical trials met our eligibility criteria, allowing us to pool data from 71 people with TRS who underwent 
C+ ECT across 4 open label trials (n=32) and 1 RCT (n=39).  The overall pooled proportion of response 
to C+ECT was 54%, (95% CI: 21.8-83.6%) with some heterogeneity evident (I2=69%). With data from 
retrospective chart reviews, case series and case reports, 192 people treated with C+ECT were 
included.  All studies together demonstrated an overall response to C+ECT of 66% (95% CI: 57.5-
74.3%) (83 out of 126 patients responded to C+ECT). The mean number of ECT treatments used to 
augment clozapine was 11.3. 32% of cases (20 out of 62 patients) with follow up data (range of follow 
up: 3-468 weeks) relapsed following cessation of ECT. Adverse events were reported in 14% of 
identified cases (24 out of 166 patients). There is a paucity of controlled studies in the literature, with 
only one single blinded randomised controlled study located, and the predominance of open label trials 
used in the meta-analysis is a limitation. The data suggests that ECT may be an effective and safe 
clozapine augmentation strategy in TRS. A higher number of ECT treatments may be required than is 
standard for other clinical indications. Further research is needed before ECT can be included in 
standard TRS treatment algorithms. 
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Title: Augmentation of clozapine with electroconvulsive therapy in treatment resistant schizophrenia: A 
systematic review and meta-analysis 
 
Introduction 
Schizophrenia is a chronic disabling illness, with a lifetime prevalence rate of 0.6-1% (Saha et al., 
2005). Approximately 30% of people with schizophrenia do not respond to conventional antipsychotic 
therapy (i.e. first or second generation antipsychotics (FGAs or SGAs) and meet the criteria for 
treatment resistant schizophrenia (TRS) (Brenner et al., 1990; Conley and Buchanan, 1997; Meltzer, 
1997). 
Clozapine remains the only effective medication for TRS, and is the only licensed treatment. However, 
30-40% of TRS patients fail to respond to clozapine (Meltzer, 1992). Those unresponsive to clozapine, 
are the most disabled of all patients with schizophrenia, with illnesses characterised by persistent 
symptoms, a poorer quality of life, increased disability and a greater economic cost than treatment 
responsive patients (Kennedy et al., 2014). Numerous pharmacological strategies have been explored, 
including the addition of a second antipsychotic, mood stabilisers, anxiolytics, antidepressants, anti-
inflammatories and glutamatergic agents, but with no robust replicated evidence to support the efficacy 
of any of these strategies (Cipriani et al., 2009; Porcelli et al., 2012; Remington et al., 2005; Taylor et 
al., 2012; Tranulis et al., 2006). 
The use of ECT in schizophrenia is supported by findings from a Cochrane review indicating that 
treatment with ECT is significantly more likely to result in clinical improvement than placebo or sham 
ECT (n=9 trials; n=400 patients), with ECT resulting in fewer relapses and increased rates of hospital 
discharge than sham ECT (Tharyan and Adams, 2005). However, recommendations for the use of ECT 
in schizophrenia are inconsistently reflected in current national clinical guidance. For example, the 
United Kingdom’s National Institute of Care Excellence (NICE) does not recommend ECT as a 
treatment for schizophrenia, unless prominent catatonia exists (NICE, 2014), whilst the American 
Psychiatric Association (APA) recommends that ECT should be considered when there is treatment 
resistance (APA, 2008). 
There is clear evidence that many users of mental health services hold negative views regarding ECT, 
although there has been little research on the attitudes of patients with treatment refractory 
schizophrenia to ECT (Rose et al., 2003; Rose et al., 2005).  Rose et al., found that perceived coercion 
and a lack of information about ECT and potential adverse effects were highlighted by patients as 
problems with their ECT treatment(Rose et al., 2005). 
A recent RCT of ECT augmentation in clozapine-resistant schizophrenia showed encouraging results 
(Petrides et al., 2015) . This prompted us to conduct an up-to-date systematic and meta-analytic review 
of the literature, to assess the efficacy of C+ECT in TRS.  We conducted a systematic review and 
meta-analysis to assess the pooled proportion of responders to C+ECT in people with TRS. Further, we 
sought to identify studies that have assessed the use of maintenance ECT in patients taking clozapine.  
We reported data on the safety and adverse effects of augmentation of clozapine with ECT, as well as 
patients’ perspectives of ECT, when any of these were reported in the identified studies.   However, we 
did not systematically search for studies reporting these aspects.  
Methods 
We performed a literature search to identify all published case series/case reports, and all 
observational and interventional studies, both RCTs and open label studies up until January 2015, 
investigating or describing ECT as a clozapine augmentation strategy in treatment resistant 
schizophrenia (TRS) and/or schizoaffective disorder. This systematic review was conducted in 
accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) 
standard (Moher et al., 2009).  
Inclusion criteria 
Studies were included in this systematic review if they: (1) included adult participants (>18 years, with 
no upper age limit) with a diagnosis of treatment resistant schizophrenia or schizoaffective disorder and 
(2) reported studies where ECT was used to augment clozapine treatment and (3) had been written in 
English and published in a peer reviewed journal since 1980.  We included both controlled and non-
controlled studies (including open label trials), as well as retrospective chart reviews or case 
series/case reports. 
Exclusion criteria 
We excluded (1) articles relating to ECT as a clozapine augmentation strategy for bipolar affective 
disorder, mania or psychotic depression, (2) studies in which clozapine was added after ECT had been 
commenced and/or (3) in which clozapine and ECT were not used concurrently.  
Information sources and searches 
Two independent reviewers (JL, JT) performed an electronic search using Medline, Embase, 
PsychInfo, Cochrane Schizophrenia Group, and Google Scholar from January 1980 until July 2015. 
The following basic search terms were used, both alone and in combinations: ‘‘schizophrenia,’’ 
‘‘clozapine,’’ ‘‘resistant,’’ ‘‘refractory,’’ and “electroconvulsive therapy,” “ECT”. In addition, the reference 
lists of the retrieved articles and relevant review articles were examined for cross-references. When 
necessary, corresponding authors were contacted to clarify study eligibility and/or acquire additional 
data.  
Study selection and exclusion 
All applicable abstracts were obtained, and independently examined by two of the authors (JL & JT). 
The two appraisers applied the eligibility criteria and a list of full text articles was developed through 
consensus. There was no search for unpublished works, although authors were contacted for 
clarification where necessary. This selection process refined the number of relevant articles to 29 
clinical reports. Two of the publications were controlled studies, and we further identified 4 open label 
studies, 2 retrospective chart reviews, 6 case series and 15 case reports. We distinguished the data 
from controlled versus non-controlled (uncontrolled) studies to achieve a workable summary of our 
findings.  
Primary outcome 
The primary outcome was the response rate to C+ECT in people with TRS and if available, to C+Sham 
ECT or no ECT. We used dichotomous data of clinical improvement, as defined by the individual 
studies, as the primary outcome measure of efficacy. These included response rates to treatment as 
measured by a pre-defined reduction in total BPRS, PANSS or CGI scores. 
Data extraction 
Articles included were critically reviewed by two authors (JL and JT) and the following information 
extracted where possible: demographic and clinical characteristics of patients, dosage and duration of 
clozapine monotherapy (before ECT), plasma clozapine levels reported pre- and post-ECT, mean 
clozapine dosage during ECT, number of ECT sessions, application of electrodes (unilateral or 
bilateral), mean ECT stimulus dosage received, clinical outcome, outcome measures used, adverse 
effects reported, information on patients’ perspectives, duration of follow-up, use of maintenance ECT 
and pattern of maintenance ECT use, other medications concurrently used during the combined 
treatment or during follow-up, and relapses reported during follow-up.   
 
Meta-Analysis 
All extracted data from the studies included were entered into Comprehensive Meta-Analysis version 
2.0 (CMA v2, Englewood, NJ, USA). 
We defined our primary outcome, response to C+ECT, according to the included study investigators' 
operational definitions of response as provided in the original reports. Where binary outcomes were 
used, we calculated the pooled proportion of those that responded with clinical improvement across all 
included studies together with 95% confidence intervals (CI)  
Due to the methodological variability in the included studies, we anticipated heterogeneity and a 
random effects meta-analysis was employed. We quantified any observed heterogeneity by computing 
the I2 statistic (Higgins et al., 2003). 
We assessed publication bias with a visual inspection of funnel plots and quantitative testing through 
the use of Begg–Mazumdar (Begg and Mazumdar, 1994) and Egger bias tests (Egger et al., 1997).  
Results 
Study selection, study and participant characteristics 
The study selection process, search results, and reasons for exclusion are given in figure 1. 
The initial search yielded 1148 references. After checking titles and abstracts, 56 full texts were 
screened and 29 of these were included for data extraction. Citations within a paper were included as 
an additional source of references. At the full text review stage we contacted 5 author groups and 3  
provided additional data to enable inclusion (Garg R et al., 2012; Grover et al., 2015; Pawełczyk et al., 
2014).  
 
Meta-Analysis 
It was possible to pool data on the proportion of responders across 71 trial participants who underwent 
ECT across 5 studies, which included 4 open label trials (n=32) and 1 RCT (n=39).  Overall, the 
proportion of people that responded to treatment was 54% (95%: CI 21.8- 83.6%) (figure 2).  There was 
evidence of some heterogeneity (I2=69%).  A subgroup analysis demonstrated that the proportion of 
those that responded was 56% (95% CI: 19.4-87.2%) in 4 open label studies and 48.7% (95%CI: 33.6-
64.0%) in the RCT.  
The funnel plot was broadly symmetrical (figure 3), and the Begg–Mazumdar (Kendall's tau=-
0.11, P= .80) and Egger bias tests (intercept =0.98, p=0.26) did not indicate any publication bias.  
We were unable to use data from the second identified RCT in the meta-analysis, as this study did not 
report a clinical response using dichotomised data of clinical improvement(Masoudzadeh and Khalilian, 
2007). Only one of the two controlled studies(Petrides et al., 2015) reported response rates in the 
treatment versus control groups, thus precluding a meta-analysis of comparisons between treatment 
groups and control groups.   
Included studies 
Table 1 gives an overview of included controlled (n=2) and open label trials (n=4) and retrospective 
chart reviews (n=2). Supplementary Table 1 gives an overview of case series included (n=6) (Benatov 
et al., 1996; Cardwell and Nakai, 1995; Frankenburg et al., 1993; Grover et al., 2015; Kales et al., 1999; 
Kurian et al., 2005). Supplementary Table 2 provides an overview of included case reports (n=15) 
(Bannour et al., 2014; Bhatia et al., 1998; Biedermann et al., 2011; Gerretsen et al., 2011; Husni M, 
1999; Keller et al., 2009; Klapheke, 1991; Lee et al., 2008; Manjunatha et al., 2011; Safferman and 
Munne, 1992; Sienaert et al., 2004; Sinha and Shah, 2013; Vowels et al., 2014; Yoshino et al., 2014) 
(Manjunatha et al., reported on two individual case reports). Overall, these studies and reports include 
a total of 192 patients with a diagnosis of treatment resistant schizophrenia or schizoaffective disorder 
treated with C+ECT.  
Controlled trials 
We identified two controlled trials. The study of Petrides et al., (Petrides et al., 2015), used a single 
blind randomised crossover design to compare clozapine use only (n=19) versus clozapine augmented 
with ECT (n=20) in patients with TRS. In this study 50% of the C+ECT group achieved treatment 
response (defined by a > 40% reduction in BPRS scores) by the end of 8 weeks compared with none of 
those in the clozapine-only group (F=5.38, df=8, 238, p<0.0001). During a subsequent crossover phase 
(unblinded), members of the clozapine-only arm who had failed to respond (which transpired to be all of 
them) were treated with C+ECT. 48% obtained a treatment response when ECT was added. A total of 
19 of the 39 participants (48.7%) had at least a 40% reduction in psychotic symptoms after receiving 
C+ECT. There was no significant difference between pre- and post-treatment global neurocognition 
scores between the two treatment groups. Further, no significant differences were found between the 
groups in the executive functioning and episodic memory domains. However, reduced processing 
speed was associated with ECT administration (with a mean decrease in the Rey Auditory Verbal 
Learning Test score of 1.5 (0.5) in the C+ECT group compared to the clozapine-only group (p=0.0063) 
when measured within 1 week of the final 8-week ECT course). Two people in the C+ECT group each 
had ECT treatment delayed by one day on one occasion, due to confusion.  
A second controlled study by Masoudzadeh et al., (total n=18) compared ECT alone (n=6), clozapine 
alone (n=6) and C+ECT (n=6)(Masoudzadeh and Khalilian, 2007).  However, it should be noted that 
the two studies differed in their inclusion criteria: in the Petrides et al., study, the main inclusion criterion 
was resistance to clozapine, whereas in Masoudzadeh et al., the main inclusion criterion was 
resistance to non-clozapine antipsychotics.  Masoudzadeh et al., did not provide a response definition; 
therefore response rates were not reported.  Instead, mean changes in PANNS scores were given.  
Compared to the pre-treatment baseline there was a significant decrease of 71% (from 99-29) in 
PANSS total scores in the C+ECT group, compared to a 40% decrease (from 99-60) with ECT 
treatment alone, and a 46% decrease (from 96-52) with clozapine monotherapy (F=189.15, df=4,63, 
p<0.0001)  (Masoudzadeh and Khalilian, 2007). In addition, compared to pre-treatment baseline, 
patients treated with C+ECT had an 80% (from 26 to 5) decrease in mean PANSS positive symptom 
subscale scores compared to the other groups (p<0.001). In the ECT alone group there was a mean 
decrease in positive symptoms of 51 % (from 25 to12); whilst in patients taking clozapine alone the 
mean decrease was 31% (from 23 to 16). The C+ECT group had a 60% decrease in mean PANSS 
negative symptom subscale score (from 33-13), with the clozapine monotherapy group having a 63% 
decrease (from 32-12). The ECT alone group had a 29% decrease (from 31-22), though the differences 
between the groups were not statistically significant. This study reported no serious adverse events in 
the C+ECT group, with no difference between Mini Mental State examination (MMSE) scores between 
the start and end of the study between the different treatment groups.  
Taken together these two controlled studies administered a mean of 15.1 ECT treatments per patient 
by pre-defined protocols. All patients had a diagnosis of TRS, but those in the Petrides et al., trial were 
additionally resistant to clozapine(Petrides et al., 2015).  Participants in the Petrides et al study were 
treated with bilateral (BL) ECT and those in the Masoudzadeh et al., 2007 treated with unilateral (UL) 
ECT(Masoudzadeh and Khalilian, 2007). 
Prospective open-label trials 
Four prospective open-label studies were found in the literature search (see table 1), with a total of 32 
patients identified. The majority of patients (n=24 out of 32) were treated with BL ECT and the mean 
number of ECT treatments was 11.6. None of the open label studies used a predetermined number of 
ECT treatments.  73% responded to ECT augmentation of clozapine in one open label trial(Kho et al., 
2004). In another study 8 out 11 patients showed significant improvements in BPRS scores (response 
defined as a BPRS decrease > 30%; with one patient showing a non-significant improvement in BPRS 
scores (an 8.2% decrease in BPRS scores) and n=2 patients showing no improvement) (Garg R et al., 
2012). Only 25% of patients showed significant improvement in PANSS total scores in another open 
label trial, though 50% had a significant reduction in PANSS positive subscale scores (Pawełczyk et al., 
2014). In a smaller study, two patients showed a significant improvement in clinical global impression 
(CGI) scores  (Hustig and Onilov, 2009).   
No adverse events were reported in two of the open label trials (n=13 patients in total (Garg R et al., 
2012; Hustig and Onilov, 2009)). In one of the studies, prolonged seizures (≥90s) were observed in 3 
patients (90, 100, and 200 seconds) (Pawełczyk et al., 2014). In the other open label study, two 
patients reported memory problems (not quantified), with one experiencing confusion following every 
ECT treatment. This patient was treated with clozapine 450 mg, lithium carbonate 1000mg and 
oxazepam 50mg  concurrent to ECT (Kho et al., 2004). No other adverse events were reported.  
Follow up data were provided in two of the trials (n=10 patients) (Hustig and Onilov, 2009; Kho et al., 
2004), with 50% (n=5) of patients in total relapsing (all in kho et al., 2004 (Kho et al., 2004)) over a 
mean follow-up period of 16 weeks (range=4–52 weeks). 
Retrospective chart reviews 
Two retrospective chart reviews were identified, with a total of 63 patients included (Gazdag et al., 
2006; Kristensen et al., 2011). All patients were treated with twice weekly BL ECT for a mean of 7.4 
ECT treatments. .  In one of the studies,  18 out of 20 patients were recorded as having an ‘excellent or 
good response to ECT augmentation’, but with 7 out of 20 requiring maintenance ECT therapy, due to 
relapses following the initial ECT treatment (Kristensen et al., 2011). In the other retrospective study 
(n=43)  the mean improvement in CGI score was 2.3(Gazdag et al., 2006). This improvement  was 
most marked in the schizoaffective disorder subgroup (n=16), where a mean decrease in CGI of 6.25 to 
2.30 was recorded, compared to a mean decrease in CGI of 5.86 to 4.65 in those with a diagnosis of 
schizophrenia (n=26, hebephrenic and catatonic subtypes). Transient side effects of headache (n=2), 
confusion (n=2) and raised systolic blood pressure (n=2) were reported (Gazdag et al., 2006).  
 
Quality of life 
We identified one secondary analysis of an open label study which quantitatively assessed quality of 
life (QoL)scores (using the World Health Organization Quality of Life Scale) of those with TRS treated 
with C+ECT (n=11). This found significant improvement in three of out of four QoL domains: 
satisfaction with physical capacity, health and environment (Garg R et al., 2012; Garg et al., 2011).   
 Case series and case reports 
The identified case series and case reports are described in supplementary tables 1 and 2. Fifty two 
patients were identified in total in the case series and case reports, and all, except one (Biedermann et 
al., 2011),were treated with BL ECT. The mean number of ECT treatments was 12.8, with a clinical 
response rate of 76% (n=28/37 patients with clinical response quantified). The mean dose of clozapine 
used concurrent to ECT was 588.5 mg daily (for a total n=26 patients with dose documented).  One 
patient died of a pulmonary embolism following ECT; the role of ECT in this was unclear 
Results summary for all 192 patients, including case series and case reports 
Taken together, the included studies and case reports, showed an overall response to clozapine 
augmented with ECT of 76% (83 out of 126 patients responded to C+ECT).  The mean number of ECT 
treatments used for all included studies and case reports (for n=192 patients) was 11.3 (range 4-30). 
The mean number of ECT treatments used in the controlled (n-2) and open label trials (n=4) was 13.0 
(for total n=77). The mean clozapine dose used was 412.3 mg daily (for n=127 patients), with a mean 
serum clozapine level of 772.6ng/ml (recorded for n=52 patients treated with an average clozapine 
dose of 506.9 mg daily (Gerretsen et al., 2011; Keller et al., 2009; Kho et al., 2004; Petrides et al., 
2015)). In those non-controlled studies, case series and case reports with follow up data, a relapse rate 
of 32% (20 out of 62 patients), was identified following an initial response to clozapine augmentation 
with ECT. Adverse events were reported in 14% of identified cases (24 out of 166 patients) (n=1 death 
secondary to pulmonary embolism; n=6 with post-ictal confusion; n=5 with prolonged seizure; n=4 with 
transient memory problems; n=3 with delirium; n=1 with aspiration pneumonia; n=2 tachycardia; n=1 
with high blood pressure; n= 1 truncal dystonia (‘Pisa syndrome’)). 
 
Discussion 
We present the first systematic review and meta-analysis of C+ECT in TRS, demonstrating a pooled 
estimate response of 54% to C+ECT. This systematic review is the most comprehensive study to date, 
incorporating newly available data and collating the available literature regarding the response to 
clozapine augmented with ECT (C+ECT) in TRS.  
We identified two randomised controlled trials both of which both demonstrated favorable results for 
C+ECT, when compared to ECT or clozapine monotherapy (Masoudzadeh and Khalilian, 2007; 
Petrides et al., 2015). These results are from the best conducted trials in this area so far; however the 
literature in this area is sparse and the methodological designs not as robust as for most 
pharmaceutical trials, owing to the difficulty of blinding. The two controlled trials were very different in 
the robustness of design and in the clinical relevance of their study findings. The Petrides et al.,(2015) 
trial addressed the important clinical question of whether ECT is a useful next step after clozapine non-
response in a treatment sequence, providing evidence that it is an effective augmentation strategy 
(Petrides et al., 2015). The smaller trial from Masoudzadeh et al., (2007) suggests that C+ECT is better 
than either ECT or clozapine alone in TRS. However, this study was limited by a small sample size, 
lack of data in relation to mean clozapine doses, dose changes during the study, and unknown serum 
clozapine levels within the different groups (Masoudzadeh and Khalilian, 2007).  The direct clinical 
relevance of this study is therefore uncertain. The findings from controlled trials are supported by 
generally positive outcomes for C+ECT in open label trials, retrospective chart reviews, case series and 
the majority of case reports.  
Our findings are broadly in line with earlier reviews that indicated that C+ECT was an efficacious and 
safe treatment for clozapine refractory psychosis (Havaki-Kontaxaki et al., 2006; Kupchik et al., 2000)). 
Our systematic review includes many more cases where C+ECT was employed as a treatment 
strategy, and this along with other findings are compared in Table 2 with the two previous systematic 
reviews of C+ECT (Havaki-Kontaxaki et al., 2006; Kupchik et al., 2000). 
Limitations of this review 
Limited primary data 
There is a paucity of controlled studies in the literature, with only one single blinded randomised 
controlled study located (Petrides et al., 2015), and the findings of that study are limited by the numbers 
recruited and the lack of a sham control group. The overreliance on open label studies in the meta-
analysis may have led to an overestimation of the identified response rate to C+ECT.  
Heterogeneity of response definitions 
Owing to the heterogeneity of response definitions, it was necessary to pool data from studies that used 
different definitions of response.  We recognise that this limits the validity of the findings.   
Publication bias  
We included one RCT and four open label trials with individual participant data in our assessment for 
publication bias in the meta-analysis. Visually, our funnel plot showed only minor asymmetry and 
Egger’s test for asymmetry was not significant (P=0.25). While this shows no evidence of publication 
bias, it is not possible to exclude given the small number of studies.   
Lack of blinding 
The absence of any double blinded data on efficacy or adverse effects limits the conclusions that can 
be drawn.  This is of particular concern with ECT given the potentially powerful placebo effect.  It is, of 
course, very difficult to conduct single blind studies of ECT, let alone double blind studies.  Sham ECT, 
where the participant is briefly anaesthetised but receives no ECT, could theoretically allow blinding, 
although the post-ictal confusion that often occurs post-ECT may unblind treatment in some cases.  
The use of sham ECT in a clinical trial requires careful ethical consideration, given that patients are 
exposed to the potential risk of anesthesia but without the potential benefits of treatment.   
English language and exclusion criteria 
We only included studies published in English. The use of ECT in schizophrenia appears to be more 
common in Asian countries, and clozapine is commonly prescribed in China, but we did not include 
Chinese databases in the systematic review. However, it is noteworthy, that the Cochrane review on 
ECT combined with antipsychotics in schizophrenia (Tharyan and Adams, 2005),  as well at this review, 
found substantial numbers of studies and reports from India and Thailand which were reported in 
English.   We were also able to recover important data from open label trials of ECT augmentation of 
antipsychotics (including clozapine) (Garg R et al., 2012; Pawełczyk et al., 2014), which allowed for 
additional C+ECT outcomes to be included.  
We excluded studies in adolescent and children. This meant that a recent observational study of ECT 
augmentation of antipsychotic treatment (which included n=6 adolescents with C+ECT) was excluded 
(Flamarique et al., 2012). 
Lack of quality of life and service user perspective 
Only one of the identified studies assessed quality of life  (Garg et al., 2011).  The assessment of 
patient and carer perception of clozapine augmentation with ECT was not reported in any of the other 
identified studies or cases.  This is an area which requires further study, and we recommend that 
service-user perspectives are included in all future controlled trials of C+ECT . The views of service 
users and carers is particularly important, given the ongoing stigma and controversy which surrounds 
ECT treatment. A well-constructed systematic review of patients’ perspectives on ECT, including a 
qualitative analysis of patient testimony, highlighted that service users perceived coercion and memory 
problems with ECT treatment in depression  (Rose et al., 2003), but this has not been investigated in in 
treatment resistant schizophrenia populations, where the balance of risks and benefits may be different.  
Implications for clinical practice 
Despite the caveats discussed above, the results suggest that ECT may be an effective augmentation 
strategy in patients who fail to respond to clozapine monotherapy.   
Number and dose of treatment required 
A consistent finding across studies is the greater number of ECT treatments used in clozapine 
augmentation in TRS than the six ECT treatments used on average in depression  (Charlson et al., 
2012; Waite and Easton, 2013). We identified an average of 15.1 ECT treatments (pre-determined ECT 
schedules) in the controlled studies, and 11 ECT treatments in all the included studies and case 
reports; the vast majority received bilateral ECT (BL-ECT) at a twice weekly frequency.  
In the best designed controlled study an average of 16 ECT treatments was used, which achieved a 
response rate of 50%. (Petrides et al., 2015) However, this was a predetermined schedule aiming for 
20 ECT treatments, and which was not based on randomised comparisons of short versus longer 
courses of treatment.  
Taken together, these data suggest, but by no means prove, that a larger number of ECT treatments 
may be required in order to achieve a response in TRS than is the case in depression.(Charlson et al., 
2012)  
Adverse effects with C+ECT 
There was a low rate of adverse events reported with ECT augmentation, but it is possible that adverse 
effects may have been under-reported, and only 4 out of 8 studies reported adverse effects in a 
systematic way.    Clozapine lowers the seizure threshold, and it has been suggested that prolonged 
seizures with ECT therapy may be precipitated by combined ECT-clozapine treatment. (Bloch et al., 
1996) Three patients in an open label trial had one individual episode each of prolonged seizure activity 
with no reported sequelae. (Pawełczyk et al., 2014) From a case series a further two patients were 
documented to have developed prolonged seizures after an ECT treatment which required treatment 
with lorazepam.(Grover et al., 2015) There were no other reports of prolonged seizure activity.   
ECT use is often limited due to concerns about cognitive side effects, including memory loss. This was 
not widely observed in our review. In the best designed controlled trial, there was no significant change 
in global neurocognition (as measured by Mental State Examination (MMSE) scores)  between baseline 
and end of ECT (Petrides et al., 2014). Additional cognitive impairment tests for executive functioning 
and episodic memory failed to identify significant differences between the C+ECT and clozapine only 
groups, though processing speed was impaired in the C+ECT group one week following the treatment 
course. 
Cognitive adverse events as determined by changes in MMSE scores, were not found in the other 
controlled study.(Masoudzadeh and Khalilian, 2007) There was a low rate of subjective reports of 
memory problems in the non-controlled studies (n=4/146 patients reported memory problems), 
although it is not clear to what extent this information was sought by the researchers and to what extent 
they relied on spontaneous reporting by the patients. There were no reports of significant cardiac 
arrhythmias, although mild cardiac adverse events of tachycardia (Bhatia et al., 1998; Safferman and 
Munne, 1992) and raised blood pressure (Safferman and Munne, 1992) were described  in case 
reports.  
In one case report, a patient died following a pulmonary embolus.(Sinha and Shah, 2013) He had been 
treated with an alternate day ECT schedule, though there is no detail given in respect to ECT dose 
used, seizure duration, and other ECT related side effects, nor is there any information given in relation 
to the dose of clozapine used at the time. There is no indication whether he was receiving treatment for 
catatonia or that a DVT was identified.   While ECT was not clearly implicated, and it is likely that the 
death led to the publication of the case report, future studies should assess whether the risks of deep 
vein thrombosis (DVT) and/or pulmonary embolism (PE) may be increased by treatment with ECT.  
Clozapine itself has been identified as a potential risk factor for venous thromboembolism, though there 
has been no systematic assessment of the prevalence of DVT or PEs associated with ECT, with there 
been only one other case report of fatal PE associated with ECT use. (Kursawe and Schmikaly, 1988) 
A handful of other case reports of PE occurring in the context of ECT exist, but again do not allow for 
definitive associations to be made.  
Follow -up data on C+ECT 
Follow-up data on patient response in the medium to longer term is lacking in the literature. This review 
noted the well-recognised problem of patients who relapse in the months following discontinuation of 
ECT. (Kho et al., 2004; Kristensen et al., 2011) We identified a high relapse rate of 32% in the weeks to 
months after ECT discontinuation, though this finding was limited by the paucity of follow up data.  
There are little data to guide practice on discontinuation of ECT. Consideration for a stabilisation period 
of ECT post remission from C+ECT may be warranted, followed by a gradual reduction in frequency of 
ECT.  
Despite the low rates of cognitive dysfunction reported in the reviewed literature, caveats regarding the 
need for monitoring for cognitive dysfunction with C+ECT use in practice remain.   
Implications for research 
We consider that double blind randomised controlled clinical trials are not only possible, but are 
essential to determine whether these encouraging findings are sustained.  The main obstacle to 
conducting a properly blinded trial is the ethical question as to whether it is justifiable to administer 
sham ECT as part of a clinical trial, whereby the patient receives an anaesthetic but no treatment.  This 
drawback may be mitigated by using crossover designs, whereby all patients receive the active 
treatment as well as the sham treatment, provided that participants have a full understanding that they 
will undergo sham ECT as part of the crossover design.  Ratings of response must be blind to 
treatment arm.   
Another barrier, which affects all studies in TRS, particularly those who have not attained a sufficient 
clinical response to clozapine, is that patients may lack capacity to consent to be recruited into clinical 
trials.  It may be appropriate in such instances to involve carers or other consultees in the decision as to 
whether to participate in the trial.   
Furthermore it is important that patient and carers are involved in the design and conduct of any study 
of ECT.  We hope that this may lead to research that allows the treatment to be tested with full 
acknowledgement and investigation of adverse effects, including memory problems, and perceptions of 
treatment with ECT in TRS both before and after the treatment.   
Longer term studies are required to assess the impact of the combination therapy on longer term 
remission, functional outcomes and adverse effects.  
Conclusions 
It is clear from this review that the efficacy and adverse effects of a C+ECT in patients with clozapine 
refractory schizophrenia remains poorly researched, most probably due to the practical challenges in 
establishing double blind ECT augmentation of clozapine trials in TRS. However a growing body of 
research from controlled and open trials and from case reports indicates that ECT may be an 
efficacious and safe clozapine augmentation strategy in TRS.   
We can conclude that ECT should not be dismissed as a potential clozapine augmentation strategy in 
TRS, and that further well controlled ECT trials are required to evaluate the efficacy of the combination 
both in the short and long term. Further research is needed to determine the place of ECT in TRS 
treatment algorithms, including greater evidence on predictors of response, adverse events, the costs 
and benefits of this treatment and the experiences of service users and carers.     
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 Table1: Controlled trials , open label prospective studies and retrospective reviews of C+ECT 
  
Study Design Cases Mean 
clozapine dose 
(+/- mean 
serum 
clozapine level) 
during ECT 
ECT 
treatment 
details 
(including 
mean no. of 
treatments,  
(SDs) 
Response Adverse events 
(AEs) 
Follow-up 
All studies  n=140 366.6mg 
(n=101) ; 
477.3 mg/L 
10.7 (n=140) 62% (n=55/89 
cases) 
7.1% (n=10/140) 40% relapsed 
(n=12/30) 
Petrides et al. 
2014 
Single blind 
RCT 
Crossover trial 
design 
39 with 
TRS 
ECT plus 
clozapine 
group=20;  
clozapine-
only 
group 
n=19 
  
518.2 mg/day 
Serum 
clozapine level 
842.2ng/ml 
15.6  B/L 
ECT 
treatments  
Twice 
weekly 
Response defined 
as decrease of ≥ 
40% from baseline 
psychotic subscale 
score on BPRS . 
50% (n=10/20) in 
C+ECT group 
responded -0% in 
the clozapine-only 
group 
Crossover sample: 
n=19 
Crossover sample 
response : 47.4% 
(9/19) 
Overall response to 
C+ECT of 48.7%, 
(19/39) 
No significant 
treatment related 
AEs. 
No significant 
difference in change 
in global neuro-
cognition between 
baseline and end of 
ECT between 
groups. 
Speed of processing 
reduced in C+ECT 
group (greater 
decrease in Rey 
Auditory Verbal 
Learning Test score 
of 1.5 (0.5) in 
C+ECT group 
compared to 
clozapine-only 
group, p=0.0063)) 
within one week of 
ECT completion 
Transient confusion 
(n=2) 
Not yet reported 
(personal 
communication) 
Masoudzadeh 
et al. 2007 
RCT 
(unblinded) 
18 with 
TRS 
6&6&6= 
3 groups 
Not reported All groups: 
12 U/L ECT 
treatments 
Three times 
weekly 
C+ECT group: 
Significant 
improvement –
Total PANSS 
reduction of 71% 
(99-29) in C+ECT 
group 
Significantly > 
greater than both 
No serious AEs. 
  
No follow-up 
ECT only and 
clozapine only 
group 
ECT only-PANSS 
total reduction of 
40% (99-60)  
& Clozapine only -
PANSS total 
reduction of 46% 
(96-52) in 
(F=189.15, df=4.63, 
p<0.001) 
 
Pawełczyk et 
al., 2014 
Open label trial 8 with 
TRS 
306.25mg/day  15.75 B/L 
(2.38) ECT 
treatments 
Three times 
weekly 
Response defined 
as decrease of  ≥  
25% in total 
PANSS : 
PANSS total 25% 
(n=2/8); 
PANSS positive 
50% (n=4/8); 
PANSS negative 
0% (0/8) 
Outcome: 
25% responded 
Prolonged seizures 
(>=90s) were 
observed in 3 
patients (90, 100, 
and 200 secs) 
No follow-up 
Garg et al 2012 Open label trial 11 with 
TRS 
  
331.8mg/day ( 
100.7) Range: 
(150 – 500mg) 
6.7  B/L 
ECT 
treatments 
(range 6-10 
ECT 
treatments)  
Response defined 
as decrease of  ≥  
30% in BPRS : 
72.7% (8/11) 
responded 
BPRS scores: 
pre ECT- 55.9 (7.2) 
decrease  to Post 
ECT-37.5 (16.3) 
(p=0.005)   
PANSS scores 
significantly 
improved: 
Pre ECT- Total 
PANSS mean score-
89.3 (18.5) 
decreased to mean 
score 67.7 (25.5) 
(p=0.008); 
No serious AEs.  
  
No follow-up 
 Hustig and 
Onilov, 2009 
Open label trial 2 with 
TRS 
Not reported 16  B/L ECT 
treatments 
ECT improved CGI 
scores: 
CGI decreased from 
6-4 
100% response rate 
None reported Clinical 
improvement 
maintained at 12 
months. 
0/2 relapsed 
Kho et al. 2004 Open label trial 11 with 
TRS 
454.5mg/day 
(range 250mg-
800mg/day) 
Serum 
clozapine  level 
440 ng/ml  
8.1 ECT 
treatments 
twice weekly 
U/L for n=10 
and B/L for 
n=3 
Response defined 
as decrease of  ≥  
30% in baseline 
Total PANSS:  
72.7% 
(n=8/11)responded 
Mean improvement 
in total PANSS 
score  of 21 
Transient memory 
problems (n=2)  
Mean follow up 
14.6 weeks Range 
(3-42) 
5/8 patients 
relapsed  
Kristensen et 
al. 2011 
Retrospective 
chart review 
20 
(TRS=15 
and TR 
SA=5) 
No dose 
reported 
10 ECT 
treatments 
(range 2-24) 
BL and twice 
weekly 
90% (18/20) 
showed an 
‘excellent or good 
response’* 
13/15 for TRS and 
5/5 for TR SA 
 7/20 cases 
required 
maintenance ECT 
Gazdag et al. 
2006 
Retrospective 
chart review 
43 with 
TRS 
(n=27) or 
TR SA 
(n=16) 
250mg/day 4.7 ECT 
treatments 
Twice 
weekly and 
B/L 
Mean change in 
CGI of 2.3. Greatest 
improvement in TR 
SA group (n=16):  
CGI decreased from 
6.25 pre-ECT to 
2.31 post-ECT. 
 No follow-up 
 
 
 
Table 2. Update from previous systematic reviews C+ECT 
 
 Kupchik, 2000 Havaki-Kontaxaki, 
2006 
Lally, 2015 
(Current review) 
 
Included RCTs 0 0 2  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Included open 
label trials and 
retrospective 
reviews 
0 1 6  
Included case 
series and case 
reports 
3 and 11  6 and 15  
Sample size 35 (17 with ECT 
added to 
clozapine) 
22 192  
Response to 
C+ECT 
67% 73% 76%  
Mean number ECT 
treatments 
12 11.5 11.3  
Adverse events 17% 23% 14%  
Follow up data: 
Sample size 
Relapse rate 
 
None reported or 
found 
 
 
22 
55% 
 
62 
32% 
 
 
Supplementary table 1. Case series of clozapine augmented with ECT in TRS 
Study No. 
cases 
Mean age  
and duration 
of illness 
(DOI) 
Mean 
Clozapine 
dose 
during 
ECT 
(and 
serum 
clozapine 
levels if 
provided) 
ECT treatment 
Details 
(including mean 
no. of treatments 
and stimulus and 
seizure duration) 
Outcome and 
measures used 
Adverse 
Events 
Maintenance 
Treatment 
Follow-up 
All cases: 37 Mean age: 
32.9 years/ 
DOI:15.4 
years 
 13.3 74% (n=20/27) 
with significant 
reduction in 
BPRS or PANNS 
scores 
10.8% 
(4/37) of 
cases with 
adverse  
events 
reported  
20% (n=4/20) 
relapsed.  
Range of follow up 
1-108 months 
Grover et al. 
2015 
11 Mean age: 
32.7 years / 
DOI:10.3 
years 
 12.8 (range 6-30) 
BL 
Mean seizure 
duration: 39.9 
seconds 
100 % (11/11 (as 
communicated 
by author) with 
significant 
reduction in 
PANSS total 
scores (>20%) 
Mean reduction 
PANSS total  
=23.2  
2 with 
‘prolonged’ 
seizure 
(duration 
not stated); 
2 with brief 
(approxima
tely 2 
hours) post 
ictal 
confusion 
No relapse , 0/11 
 
Duration of follow-
up: 6 moths-108 
month 
Kurian at al. 
2005 
3 with 
TRS 
Mean age: 26 
years/ 
 8-10 ECT 
treatments 
All with a 40-
50% reduction in 
BPRS scores 
None. No follow-up 
reported 
Kales et al. 
1999 
5 with 
TRS 
Mean age: 
49.1 years 
Mean DOI: 
29.4 years 
540mg/day 
(200-
900mg/day
) 
12.2 ECT 
treatments (range 
5-12) 
BL 
PANSS (n=2) 
Mean 
improvement 
of48.5 (123.5-75) 
 
CGI (n=5) Mean 
improvement 1.8 
(6-4); 
Mean GAF 
improvement: 22 
(range-15-55) 
 
None 3/5 relapsed. 
Duration of follow-
up  4-104 weeks 
One required 
additional ECT 
courses due to 
relapse within 1 
month of 
discontinuation 
Benatov et 
al. 1996 
4 with 
TRS 
Age N/A 
Mean DOI: 
18.25 years 
 14.25 ECT 
treatments 
BPRS (n=3) 
One patient 
‘completely 
recovered’ 
Decrease in 
BPRS scores 
>50% in another. 
Other two BPRS 
None ¾ no relapse 
reported at follow 
up; duration of 6 to 
24 months of 
follow -up 
Maintenance dose  
of clozapine 
average 400mg 
  
 
 
 
 
 
 
 
scores decrease 
from 71.5 to 42; 
>40% 
improvement in 
BPRS in 3 
cases; modest 
effect in other 
case 
  
/day 
Cardwell et 
al. 1995 
5 
(PS=4; 
SA=3) 
Mean age: 
41.25 years 
 21.6 ECT 
treatments (17-31) 
26.9% 
improvement in 
total BPRS; 
25.3% 
improvement in 
positive BPRS 
scores; 
21.3% 
improvement in 
negative BPRS 
scores; 
 
None No follow-up 
reported 
Frankenbur
g et al. 1993 
9 (n=2 
Schiz; 
n=7 
SA) 
Mean Age: 
36.3years 
Mean DOI: 
14.6 years 
75-
550mg/day 
11 ECT treatments 
Seizure duration: 
54.2 seconds 
3 Pts: 
marked/moderat
e response =3; 
minimal 
response =3 
minimal/ 
no response=3 
None No follow-up 
reported 
  
 
 
 
 
 
 
 
 
 
Supplementary table 2. Case reports of clozapine augmented with ECT in TRS 
Case 
Patient 
age 
and 
gender 
Diagnosis as 
reported 
and duration 
of illness 
Clozapine 
dose when 
ECT 
commence
d 
(and serum 
levels if 
provided) 
Psycho-
tropic 
medication 
during 
ECT 
(and 
serum 
levels if 
provided) 
ECT 
treatment 
Details 
(including 
mean 
stimulus if 
provided) 
Outcome 
and 
measures 
used 
Adverse 
Events 
Maintenance 
Treatment 
Follow-up 
All cases 
(n=15) 
31.5 
years 
14 with TRS 
and 1 with TR 
SAD 
 
Mean dose: 
626.7mg 
11.6 (14/15 
with BL ECT) 
80% 
responded to 
C+ECT 
(n=8/10) 
Adverse 
effects were 
reported in 
11/15.  
n=4 :mild and 
transient  
n=4: adverse 
effects led to 
discontinuation 
of ECT. 
N=1:death 
secondary to 
PE  
44%(n=4/9) 
relapsed  
 
33% (n=4/12) 
maintenance 
ECT for longer 
than 1 month 
Bannour 
et al (2014) 
 
32, 
Female 
Undifferen-
tiated 
Schizophrenia
, 11 years 
700mg bd 
Clozapine 
700mg bd 
16 sessions of 
BL ECT 
(3 sessions 
per week) 
 
BPRS 
score 
decreased 
from 95 to 29 
None reported 
 
ECT 
Continued at 
the 
rate of 1 
session per 
month.  
 
After 24 
sessions, 
patient was 
‘well 
stabilized’, 
and 
functioning 
socially 
 
Bhatia  
et al (1998) 
35,  
Male  
Paranoid 
Schizophrenia
, 4 years 
850mg daily 
 
 
Pimozide 
(during 
ECT course 
1 and 2) 
 
Clozapine 
(during 
ECT course 
3, titrated 
during 
treatment 
to 800mg) 
 
 
Clonazepa
m 0.5mg 
tds 
 
 
3 courses of 
bilateral ECT 
during 60-
week hospital 
stay: 13, 10 
and 9 
sessions 
BPRS from 
69 on 
admission to 
37 on 
discharge 
Seizure at 20 
months, 
unrelated to 
ECT, changed 
to Olanzapine 
No further 
ECT 
 
Discharged to 
community 
 
Stable at 20 
months  
Biederman
n et al 
(2011) 
39,  
Male 
Paranoid 
Schizophrenia
, over 20 
years 
300mg daily 
(previously 
up to 
800mg) 
Clozapine 
300mg 
daily 
 
12 right 
unilateral ECT 
sessions 
PANSS total 
decreased 
from 78 at 
baseline to 
67 one 
month post 
ECT  
Slight 
cognitive 
improve-
ments were 
measured, 
None reported Not reported 
and these 
continued at 
least 1 
month after 
ECT 
Gerretsen 
et al (2011) 
39, 
Male 
‘Refractory 
schizophrenia 
with a 
strong 
affective 
component’ 
450mg bd; 
743 ng/mL; 
(previous 
augmentatio
n with 
Valproate 
d/c on 
starting 
ECT) 
Clozapine 
450mg bd 
15 bilateral 
ECT 
treatments 
 
 
Specifications: 
pulse width, 
1.0; 
frequency, 60 
Hz; duration, 
6.0 seconds; 
charge, 
576 mC; 
seizure 
duration, 
27-59 
seconds) 
BPRS: 3 
months 
before ECT 
= 64; during 
ECT 26 
 
 
Cognitive 
dysfunction on 
days of 
treatment  
 
(MMSE 
improved from 
27/30 to 29/30 
between ECT 
and 
MoCA 
improved from 
22/30 to 25/30 
between 
treatments) 
  
Abnormal EEG 
after 15 
treatments- 
suggestive of 
encephelopathi
c clinical 
picture 
  
Maintained on 
clozapine and 
reduced to 
twice weekly 
bilateral ECT 
for 3 weeks. 
 
Delusional 
preoccupation
s intensified 
between 
treatments 
 
(BPRS = 42) 
 
ECT 
discontinued 
owing to the 
risk of 
cognitive 
deficits with 
prolonged 
treatment. 
. 
Keller  
et al (2009) 
19, 
Male 
Paranoid 
Schizophrenia
, 6 years 
1600 mg 
daily; 917 
ng/mL 
(previously 
up to 
1800mg 
daily) 
Increased 
to 1700mg 
during 
treatment; 
1083ng/mL 
8 weeks 
bilateral ECT 
(3/week for 4 
weeks, 
2/week for 4 
weesk) 
BPRS 
From 34 pre-
treatment to 
30 post-
treatment 
Postictal 
confusion and 
mild difficulties 
with 
anterograde 
memory 
1 per week for 
4 weeks 
Klapeheke 
et al 
(1991) 
26, 
Female 
Schizoaffectiv
e Disorder, 
Bipolar type 
(duration not 
reported) 
450mg daily 
 
Titrated 
during ECT 
to 600mg 
daily 
 
9 sessions 
bilateral, brief 
pulse ECT- 14 
adequate 
seizures 
 
(Pulse freq 
50/0Hz 
Pulse width 
0.75 or 1.5ms 
Duration 1.25 
or 1.5s) 
‘Dramatic 
clinical 
response 
with 
resolution of 
hallucination
s, delusions 
and thought 
disorder 
Tachycardia 
only 
Sustained 
improvement 
over 3 weeks 
with continued 
upward 
titration of 
Clozapine (to 
400mg bd) 
Lee WK  
et al (2008) 
57,  
Female 
Schizophrenia
, 
30 years 
400mg daily 
Clozapine 
400mg 
daily 
10 sessions 
bilateral ECT, 
then 
discontinued 
due to a/e* 
 
- 
*PISA 
SYNDROME  
Clozapine 
reduced to 
25mg due to 
s/e, then 
maintained at 
300mg after 
Manjunath
a et al 
(2011) 
 
CASE 1 
39,  
Male 
Paranoid 
Schizophrenia
,  
(duration not 
reported) 
400mg daily 
Clozapine 
400mg 
daily 
Bitemporal, 
thrice-weekly, 
suprathreshol
d, modified 
ECT 
 
Stopped after 
12
th
 session 
due to a/e* 
- *DELIR-IUM 
Complete 
recovery from 
delirium within 
48 h without 
any further 
complic-
ations; 
Clozapine was 
restarted after 
2 days; dose 
gradually 
increased to 
150 mg 
Manjunath
a et al 
(2011) 
 
CASE 2 
40,  
Male 
Paranoid 
Schizophrenia
,  
(duration not 
reported) 
300mg daily 
Clozapine 
300mg 
daily 
 
Bitemporal, 
thrice-weekly, 
suprathreshol
d, modified 
ECT 
 
Stopped after 
6
th
 session 
due to a/e* 
- 
*DELRIUM and 
ASPIRATION 
PNEUMONITI
S 
Following 
recovery, 
Clozapine 
monotherapy 
was restarted 
at a dose of 
300 mg/day 
without re-
emergence of 
delirium 
 Safferman 
et al (1992) 
33, 
Female 
Paranoid 
Schizophrenia
, 10 years 
400mg daily  
Clozapine 
400mg 
daily, 
Lorazepam 
tapered 
and 
stopped 
after 3
rd
 
ECT 
8 bilateral 
ECT sessions 
 
(pulse freq 60-
80hz, pulse 
width 1.4-
1.6ms, 
stimulus 
duration 1.4-
1.6s) 
Positive 
symptoms 
‘markedly 
reduced in 
intensity’, 
improved 
sociality 
Mild 
hypertension 
and 
tachycardia 
Clozapine 
increased to 
450mg; after 3 
weeks 
discharged 
Sieneart  
et al (2004) 
37,  
Male 
Paranoid 
Schizophrenia 
(duration not 
reported) 
600mg daily 
 
Clozapine 
600mg 
daily 
 
Reduced to 
450mg 
daily after 
3
rd
 
treatment 
due to a/e* 
Bilateral ECT, 
11 treatments  
 
(Pulse width 
0.5 
milliseconds, 
frequency 30 
Hz, 
duration 5 
seconds, 
charge 120 
mC, current 
800 mA) 
Hours and 
days after 1
st
 
treatment:   
‘remarkable 
diminishment 
of anxiety, 
hostility, and 
agitation’ 
 
CDSS 
6 at baseline, 
1 after the 
11th 
treatment. 
  
PECC  
80 
before the 
start of 
treatment, 38 
after the 11th 
treatment. 
Motor agitation 
and confusion 
directly after 1
st
 
treatment 
 
*Severe 
delirium after 
3
rd
 treatment 
 
Further 
episodes of 
delirium 
following 
further 
treatments 
Maintenance-
ECT on a 
once a- 
week schedule 
 
No further 
data on 
outcome 
reported 
Sinha  
et al, 2013 
22, 
Male 
Paranoid 
Schizophrenia 
(duration not 
reported) 
100mg daily 
Clozapine 
100mg 
daily 
4 ECT 
treatments 
- 
Patient died 
from 
pulmonary 
embolism after 
4
th
 treatment 
- 
Vowels 
et al (2014) 
Female
, 
18 
Schizophrenia 
and Moderate 
Intellectual 
Disability, 
(duration not 
reported) 
500mg daily 
Clozapine 
500mg 
daily 
1
st
 Treatment: 
8 ECT 
sessions 
 
 
2
nd
 Treatment: 
12 ECT 
sessions 
 
 
 
 
 
1
st
 
Treatment: 
significant 
improvement 
was 
observed 
with no 
evidence of 
ongoing 
auditory 
hallucination
s 
or physical 
aggression. 
 
 
2
nd
 
Treatment: 
‘again 
result[ed] in 
improvement
’ 
 
Relapse after 
1-2 weeks 
after both 
treatments 
None reported 
‘With 
continuation 
ECT (currently 
at a total of 
more than 35 
sessions), 
continues to 
show 
behavioural 
stability, is 
able to attend 
school, and 
has been 
discharged to 
supported 
community 
accommodatio
n 
following a 16 
month 
admission’ 
Yoshino 
et al (2014) 
Female
, 
37 
Schizophrenia
, 
11 years 
500mg daily 
Clozapine 
500mg  
Bilateral ECT- 
10 treatments 
(2 or 3 per 
week) 
 
BPRS 
Before 
Clozapine:  
81; on 
Clozapine: 
reduced to 
67; 
after one 
course of 
ECT reduced 
to 40 
Anterograde 
amnesia- 
resolved after 
a few hours 
Continuation 
(maintenance) 
ECT was then 
done twice 
every 4 weeks 
and there 
were no 
significant ill 
effects. 
Maintenance 
ECT 
 
 
 
 
